pentoxifylline has been researched along with Fatty Liver, Nonalcoholic in 33 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to assess and compare the effect of fenofibrate alone or in combination with pentoxifylline on the measured biochemical parameters, inflammatory pathway and liver stiffness in patients with non-alcoholic fatty liver disease." | 9.20 | Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. ( El-Haggar, SM; Mostafa, TM, 2015) |
| "Pentoxifylline therapy results in weight loss, improved liver function and histological changes in patients with NAFLD/NASH." | 8.90 | Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. ( Du, J; Li, YM; Ma, YY; Yu, CH, 2014) |
| "This quasi experimental study was carried out to compare the efficacy of Pentoxifylline versus Pioglitazone in non-alcoholic fatty liver disease (NAFLD) among newly detected glucose intolerant patients attended at GHPD, BIRDEM, Dhaka, Bangladesh from March 2011 to May 2012." | 7.83 | Comparative Study between Pentoxifylline and Pioglitazone in the Treatment of Non-Alcoholic Fatty Liver Disease among Newly Detected Glucose Intolerant Patients. ( Ahmed, H; Alam, MS; Chowdhury, M; Karim, MR; Paul, RK; Saha, A, 2016) |
| "Pentoxifylline has been used to treat nonalcoholic fatty liver diseases (NAFLDs) due to its anti-tumor necrosis factor-α effects." | 6.50 | Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. ( Xie, KQ; Zeng, T; Zhang, CL; Zhao, XL, 2014) |
| "Pentoxifylline-treated patients showed a significant decrease AST (n=37, P=0." | 6.47 | Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. ( Cheng, X; Li, W; Qing, L; Qu, S; Sheng, C; Zheng, L, 2011) |
| "Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake." | 5.43 | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. ( Chang, ML; Chao, J; Cheng, HY; Liao, JW; Pao, LH; Peng, WH; Ye, JH, 2016) |
| "The purpose of this study was to assess and compare the effect of fenofibrate alone or in combination with pentoxifylline on the measured biochemical parameters, inflammatory pathway and liver stiffness in patients with non-alcoholic fatty liver disease." | 5.20 | Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. ( El-Haggar, SM; Mostafa, TM, 2015) |
| " pylori-associated erosive gastritis with non-alcoholic steatohepatitis after eradication therapy with and without addition of pentoxifylline." | 5.17 | [Microcirculatory changes of gastric mucosa in patients with chronic H. pylori-associated erosive gastritis with non-alcoholic steatohepatitis during treatment]. ( Dolhaia, NIe; Kuryk, OH; Solovŭova, HA; Svintsits'kyĭ, AS, 2013) |
| " Therapy with PTX resulted in significant decreases in 9-HODE and 13-oxoODE, oxidized lipid products of linoleic acid (LA) linked to histological severity in nonalcoholic fatty liver disease." | 5.16 | Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. ( Feldstein, AE; Fu, X; Hazen, SL; Kirwan, JP; Lopez, R; McCullough, AJ; Yerian, LM; Zein, CO, 2012) |
| "Pentoxifylline therapy results in weight loss, improved liver function and histological changes in patients with NAFLD/NASH." | 4.90 | Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. ( Du, J; Li, YM; Ma, YY; Yu, CH, 2014) |
| "Pentoxifylline significantly alleviated hepatic lipid accumulation, reduced blood lipid levels and improved insulin resistance." | 4.12 | Pentoxifylline attenuates nonalcoholic fatty liver by inhibiting hepatic macrophage polarization to the M1 phenotype. ( Feng, Y; Liu, H; Ping, J; Wen, X; Xu, D; Zhao, W, 2022) |
| "This quasi experimental study was carried out to compare the efficacy of Pentoxifylline versus Pioglitazone in non-alcoholic fatty liver disease (NAFLD) among newly detected glucose intolerant patients attended at GHPD, BIRDEM, Dhaka, Bangladesh from March 2011 to May 2012." | 3.83 | Comparative Study between Pentoxifylline and Pioglitazone in the Treatment of Non-Alcoholic Fatty Liver Disease among Newly Detected Glucose Intolerant Patients. ( Ahmed, H; Alam, MS; Chowdhury, M; Karim, MR; Paul, RK; Saha, A, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) defines fat accumulation in the liver, and it is commonly associated with metabolic syndromes like diabetes and obesity." | 2.82 | A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. ( Ezhilarasan, D; Lakshmi, T, 2022) |
| "However, most patients with NAFLD/NASH will die from a vascular cause." | 2.72 | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. ( Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is recognized as a global health problem and as a common cause of chronic liver disease." | 2.55 | Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. ( Bush, H; Golabi, P; Younossi, ZM, 2017) |
| "Pharmacotherapy for nonalcoholic fatty liver disease (NAFLD) has not yet been approved by the US Food and Drug Administration." | 2.55 | Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. ( Mao, YM; Tang, JT, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in the USA with a growing prevalence worldwide." | 2.53 | Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. ( Corey, KE; Rinella, ME, 2016) |
| "The prevalence of nonalcoholic fatty liver disease (NAFLD) has significantly increased over the last decades." | 2.53 | Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. ( Chaiyakunapruk, N; Chongmelaxme, B; Kowdley, KV; Phisalprapa, P; Saokaew, S; Sawangjit, R; Thakkinstian, A, 2016) |
| "Nonalcoholic fatty liver disease is the most common cause of chronic liver disease in Western countries, and consists of a spectrum of histopathological changes that range in severity from simple steatosis to steatohepatitis to cirrhosis." | 2.50 | State of the art: treatment of nonalcoholic steatohepatitis. ( Loomba, R; Pearlman, M, 2014) |
| "Pentoxifylline has been used to treat nonalcoholic fatty liver diseases (NAFLDs) due to its anti-tumor necrosis factor-α effects." | 2.50 | Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. ( Xie, KQ; Zeng, T; Zhang, CL; Zhao, XL, 2014) |
| "Although it is easy to diagnose NAFLD, a liver biopsy is currently required to diagnose nonalcoholic steatohepatitis (NASH)." | 2.48 | Nonalcoholic fatty liver disease. ( Harrison, SA; Paredes, AH; Torres, DM, 2012) |
| "Pentoxifylline-treated patients showed a significant decrease AST (n=37, P=0." | 2.47 | Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. ( Cheng, X; Li, W; Qing, L; Qu, S; Sheng, C; Zheng, L, 2011) |
| "Non-alcoholic fatty liver disorders (NAFLD), particularly non-alcoholic steatohepatitis (NASH), have emerged as a leading cause of liver transplantation and mortality." | 1.72 | Pentoxifylline and its association with kaempferol improve NASH-associated manifestation in mice through anti-apoptotic, anti-necroptotic, antioxidant, and anti-inflammatory mechanisms. ( Abdel-Hamed, AR; Abo-Elmatty, DM; Ghattas, MH; Hamouda, AO; Khedr, NF, 2022) |
| "The early inclusion of patients with NAFLD and severe asthenic syndrome in the treatment regimen, in addition to the basic therapy of Cytoflavin, achieved a significantly high therapeutic effect in the form of normalization of the main clinical, laboratory and instrumental parameters, as well as a significant reduction in the manifestations of asthenia." | 1.62 | [Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome]. ( Eremin, MN; Ivolgin, AF; Karakozov, AG; Katenko, SV; Levchenko, OB; Molodova, AI; Pavlov, AI, 2021) |
| "Animals without steatosis (ie NAFLD) at week 16 were excluded from the data analysis." | 1.62 | The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis. ( Andersen, M; Buelund, LE; Ipsen, DH; Latta, M; Lintrup, K; Lykkesfeldt, J; Skaarup, R; Skat-Rørdam, J; Svenningsen, M; Tveden-Nyborg, P, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease linked to insulin resistance, oxidative stress, and cytokine imbalance." | 1.56 | Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats. ( Abdel-Latif, RG; El-Deen, RM; Heeba, GH; Khalifa, MMA, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake." | 1.43 | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. ( Chang, ML; Chao, J; Cheng, HY; Liao, JW; Pao, LH; Peng, WH; Ye, JH, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (72.73) | 24.3611 |
| 2020's | 9 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Fouda, A | 1 |
| Abdelaziz, AE | 1 |
| Hussien, M | 1 |
| Ali, AA | 1 |
| Abdelkawy, KS | 1 |
| Elbarbry, F | 1 |
| Ezhilarasan, D | 1 |
| Lakshmi, T | 1 |
| Xu, D | 1 |
| Zhao, W | 1 |
| Feng, Y | 1 |
| Wen, X | 1 |
| Liu, H | 1 |
| Ping, J | 1 |
| Pavlov, AI | 1 |
| Ivolgin, AF | 1 |
| Katenko, SV | 1 |
| Eremin, MN | 1 |
| Molodova, AI | 1 |
| Levchenko, OB | 1 |
| Karakozov, AG | 1 |
| Hamouda, AO | 2 |
| Abdel-Hamed, AR | 2 |
| Abo-Elmatty, DM | 2 |
| Khedr, NF | 2 |
| Ghattas, MH | 2 |
| El-Deen, RM | 1 |
| Heeba, GH | 1 |
| Abdel-Latif, RG | 1 |
| Khalifa, MMA | 1 |
| Mahjoubin-Tehran, M | 1 |
| De Vincentis, A | 1 |
| Mikhailidis, DP | 1 |
| Atkin, SL | 1 |
| Mantzoros, CS | 1 |
| Jamialahmadi, T | 1 |
| Sahebkar, A | 1 |
| Ipsen, DH | 1 |
| Skat-Rørdam, J | 1 |
| Svenningsen, M | 1 |
| Andersen, M | 1 |
| Latta, M | 1 |
| Buelund, LE | 1 |
| Lintrup, K | 1 |
| Skaarup, R | 1 |
| Lykkesfeldt, J | 1 |
| Tveden-Nyborg, P | 1 |
| Kedarisetty, CK | 1 |
| Bhardwaj, A | 1 |
| Kumar, G | 1 |
| Rastogi, A | 1 |
| Bihari, C | 1 |
| Kumar, M | 1 |
| Sarin, SK | 1 |
| Lombardi, R | 1 |
| Onali, S | 1 |
| Thorburn, D | 1 |
| Davidson, BR | 1 |
| Gurusamy, KS | 1 |
| Tsochatzis, E | 1 |
| Golabi, P | 1 |
| Bush, H | 1 |
| Younossi, ZM | 1 |
| Tang, JT | 1 |
| Mao, YM | 1 |
| Du, J | 1 |
| Ma, YY | 1 |
| Yu, CH | 1 |
| Li, YM | 1 |
| Svintsits'kyĭ, AS | 1 |
| Solovŭova, HA | 1 |
| Kuryk, OH | 1 |
| Dolhaia, NIe | 1 |
| Pearlman, M | 1 |
| Loomba, R | 1 |
| Zeng, T | 1 |
| Zhang, CL | 1 |
| Zhao, XL | 1 |
| Xie, KQ | 1 |
| Metwally, AH | 1 |
| Yalcin, M | 1 |
| Akarsu, M | 1 |
| Celik, A | 1 |
| Sagol, O | 1 |
| Tunali, S | 1 |
| Ertener, O | 1 |
| Bengi, G | 1 |
| Akpinar, H | 1 |
| El-Haggar, SM | 1 |
| Mostafa, TM | 1 |
| Shirakami, Y | 1 |
| Shimizu, M | 1 |
| Kubota, M | 1 |
| Ohno, T | 1 |
| Kochi, T | 1 |
| Nakamura, N | 1 |
| Sumi, T | 1 |
| Tanaka, T | 1 |
| Moriwaki, H | 1 |
| Seishima, M | 1 |
| Corey, KE | 1 |
| Rinella, ME | 1 |
| Ganesh, S | 1 |
| Rustgi, VK | 1 |
| Karim, MR | 1 |
| Ahmed, H | 1 |
| Paul, RK | 1 |
| Chowdhury, M | 1 |
| Alam, MS | 1 |
| Saha, A | 1 |
| Sawangjit, R | 1 |
| Chongmelaxme, B | 1 |
| Phisalprapa, P | 1 |
| Saokaew, S | 1 |
| Thakkinstian, A | 1 |
| Kowdley, KV | 1 |
| Chaiyakunapruk, N | 1 |
| Ye, JH | 1 |
| Chao, J | 1 |
| Chang, ML | 1 |
| Peng, WH | 1 |
| Cheng, HY | 1 |
| Liao, JW | 1 |
| Pao, LH | 1 |
| Li, W | 1 |
| Zheng, L | 1 |
| Sheng, C | 1 |
| Cheng, X | 1 |
| Qing, L | 1 |
| Qu, S | 1 |
| Zaitone, S | 1 |
| Hassan, N | 1 |
| El-Orabi, N | 1 |
| El-Awady, el-S | 1 |
| Zein, CO | 2 |
| Yerian, LM | 2 |
| Gogate, P | 1 |
| Lopez, R | 2 |
| Kirwan, JP | 2 |
| Feldstein, AE | 2 |
| McCullough, AJ | 2 |
| Sterling, RK | 1 |
| Sanyal, AJ | 1 |
| Chae, MK | 1 |
| Park, SG | 1 |
| Song, SO | 1 |
| Kang, ES | 1 |
| Cha, BS | 1 |
| Lee, HC | 1 |
| Lee, BW | 1 |
| Fu, X | 1 |
| Hazen, SL | 1 |
| Hemsworth-Peterson, TC | 1 |
| Paredes, AH | 1 |
| Torres, DM | 1 |
| Harrison, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Project to Study the Efficacy of Combined Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis[NCT01384578] | Phase 3 | 0 participants (Actual) | Interventional | 2011-07-31 | Withdrawn (stopped due to Lack of funds) | ||
| Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158] | Phase 3 | 56 participants (Anticipated) | Interventional | 2022-11-30 | Not yet recruiting | ||
| Treatment Efficacy of Pentoxifylline in Patients With Nonalcoholic Steatohepatitis: A Double-blind Randomized Placebo Controlled Trial[NCT00590161] | Phase 2 | 55 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The NAFLD Activity Score (NAS) grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and balloning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis(assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2). (NCT00590161)
Timeframe: 1 year (Baseline liver biopsy done at study entry, and subsequent liver biopsy done after one year of therapy with pentoxifylline or placebo)
| Intervention | NAS score units (Mean) |
|---|---|
| Pentoxifylline 400 mg PO Tid | -1.6 |
| Placebo Tid | -0.1 |
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
13 reviews available for pentoxifylline and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
Topics: Antioxidants; Humans; Liver; Liver Neoplasms; NF-kappa B; Non-alcoholic Fatty Liver Disease; Pentoxi | 2022 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Di | 2021 |
Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
Topics: Anticholesteremic Agents; Antioxidants; Bile Acids and Salts; Humans; Network Meta-Analysis; Non-alc | 2017 |
Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Topics: Antioxidants; Chenodeoxycholic Acid; Cholic Acids; Diet Therapy; Exercise; Free Radical Scavengers; | 2017 |
Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
Topics: Antioxidants; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyp | 2017 |
Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.
Topics: Biomarkers; Humans; Liver; Liver Function Tests; Non-alcoholic Fatty Liver Disease; Pentoxifylline; | 2014 |
State of the art: treatment of nonalcoholic steatohepatitis.
Topics: Antioxidants; Exercise; Humans; Hypoglycemic Agents; Life Style; Non-alcoholic Fatty Liver Disease; | 2014 |
Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Humans; Non-alcoholic Fatty Liver Dise | 2014 |
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Topics: Antioxidants; Bariatric Surgery; Exercise; Fatty Acids, Omega-6; Humans; Hydroxymethylglutaryl-CoA R | 2016 |
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
Topics: Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anti | 2016 |
Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.
Topics: Antioxidants; Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Thia | 2016 |
Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease.
Topics: Cytokines; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Phosphodiesterase | 2011 |
Nonalcoholic fatty liver disease.
Topics: Antioxidants; Biomarkers; Cholagogues and Choleretics; Diabetes Complications; Fatty Acids, Omega-3; | 2012 |
6 trials available for pentoxifylline and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
Topics: Adult; Antioxidants; Cholagogues and Choleretics; Disease Progression; Egypt; Female; Humans; Male; | 2021 |
Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study.
Topics: Adolescent; Adult; Alanine Transaminase; Antioxidants; Drug Therapy, Combination; Female; Humans; Li | 2021 |
[Microcirculatory changes of gastric mucosa in patients with chronic H. pylori-associated erosive gastritis with non-alcoholic steatohepatitis during treatment].
Topics: Adult; Drug Therapy, Combination; Fatty Liver; Female; Gastric Mucosa; Gastritis; Helicobacter Infec | 2013 |
Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease.
Topics: Adult; Blood Glucose; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyaluronic Acid; Hypol | 2015 |
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
Topics: Adiponectin; Adult; Alanine Transaminase; Apoptosis; Aspartate Aminotransferases; Biopsy; Fatty Live | 2011 |
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
Topics: Adiponectin; Adult; Alanine Transaminase; Apoptosis; Aspartate Aminotransferases; Biopsy; Fatty Live | 2011 |
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
Topics: Adiponectin; Adult; Alanine Transaminase; Apoptosis; Aspartate Aminotransferases; Biopsy; Fatty Live | 2011 |
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
Topics: Adiponectin; Adult; Alanine Transaminase; Apoptosis; Aspartate Aminotransferases; Biopsy; Fatty Live | 2011 |
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism.
Topics: Adult; Biopsy, Needle; Blood Chemical Analysis; Dose-Response Relationship, Drug; Double-Blind Metho | 2012 |
14 other studies available for pentoxifylline and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Pentoxifylline attenuates nonalcoholic fatty liver by inhibiting hepatic macrophage polarization to the M1 phenotype.
Topics: Animals; Cholesterol; Eosine Yellowish-(YS); Glucose; Insulin Resistance; Insulins; Lipopolysacchari | 2022 |
[Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome].
Topics: Asthenia; Humans; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Saline Solution; Syndrome | 2021 |
Pentoxifylline and its association with kaempferol improve NASH-associated manifestation in mice through anti-apoptotic, anti-necroptotic, antioxidant, and anti-inflammatory mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Kaempferols; Liver; Male; Mice; Mice, Inbred C57BL; | 2022 |
Pentoxifylline and its association with kaempferol improve NASH-associated manifestation in mice through anti-apoptotic, anti-necroptotic, antioxidant, and anti-inflammatory mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Kaempferols; Liver; Male; Mice; Mice, Inbred C57BL; | 2022 |
Pentoxifylline and its association with kaempferol improve NASH-associated manifestation in mice through anti-apoptotic, anti-necroptotic, antioxidant, and anti-inflammatory mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Kaempferols; Liver; Male; Mice; Mice, Inbred C57BL; | 2022 |
Pentoxifylline and its association with kaempferol improve NASH-associated manifestation in mice through anti-apoptotic, anti-necroptotic, antioxidant, and anti-inflammatory mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Kaempferols; Liver; Male; Mice; Mice, Inbred C57BL; | 2022 |
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats.
Topics: Animals; Antioxidants; Biomarkers; Cilostazol; Diet, High-Fat; Fatty Liver; Inflammation; Insulin; I | 2020 |
The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis.
Topics: Animals; Aspirin; Diet, High-Fat; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Reposit | 2021 |
Pentoxifylline in the management of metabolic syndrome and chronic hepatitis C.
Topics: Antiviral Agents; Cardiovascular Diseases; Hepatitis C, Chronic; Humans; Insulin Resistance; Liver C | 2014 |
A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis.
Topics: Adalimumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Infliximab; Male; No | 2014 |
Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis.
Topics: Animals; Diabetes Mellitus, Experimental; Inflammation; Lipogenesis; Liver Neoplasms, Experimental; | 2016 |
Comparative Study between Pentoxifylline and Pioglitazone in the Treatment of Non-Alcoholic Fatty Liver Disease among Newly Detected Glucose Intolerant Patients.
Topics: Adult; Bangladesh; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Non- | 2016 |
Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dyslipidemias; Fa | 2016 |
Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Biomarkers; Body Weight; C | 2011 |
Pentoxifylline for steatohepatitis: magic bullet or smoking gun?
Topics: Fatty Liver; Female; Humans; Liver; Male; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Platele | 2011 |
Pentoxifylline attenuates methionine- and choline-deficient-diet-induced steatohepatitis by suppressing TNF-α expression and endoplasmic reticulum stress.
Topics: Alanine Transaminase; Animals; Cell Line; Choline Deficiency; Diet; Endoplasmic Reticulum Stress; Fa | 2012 |
The mechanism behind the novel fibrosis recently described in NASH in HEPATOLOGY 2011 and elsewhere.
Topics: Cohort Studies; Fatty Liver; Female; Forecasting; Gastroenterology; Hepatitis C, Chronic; Humans; Li | 2012 |